StreetAlpha.app
Home › Stocks › GRAL

GRAIL, Inc. (GRAL)

Healthcare
$105.88
▲ +0.27%
LAST CLOSE · NOV 17

GRAIL develops Galleri, a blood test that screens for many types of cancer at once. It last closed at $105.88 on Nov 17, up 0.27% on the day. The average 12-month price target from 9 analysts is $136.44 (+28.9% from the last close), with a high of $180.00 and a low of $100.00. Analyst consensus is Buy, based on the latest ratings from 9 firms (5 buy, 4 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in GRAL, 50% of them bullish and 50% bearish. In the past 30 days there were 1 dark pool print totaling $535K, the largest $535K.

AI Auto Pilots
Is GRAL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$166.6M
+17.5% vs a year ago
Net income
−$406.2M
−243.8% margin
EPS (diluted)
−$9.22
Free cash flow
−$312.0M
−187.3% margin
Valuation
Market cap
$4.8B
45.0M shares
P/E
–
No P/E while losing money
Price to sales
28.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.0M
At Sep 30
Shareholder equity
$2.5B
Shares outstanding
45.0M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $55.5M$55.5MFY2023FY2023: $93.1M$93.1MFY2023FY2024: $125.6M$125.6MFY2024FY2025: $147.2M$147.2MFY2025

From GRAL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 9 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
9firms
5 Buy4 Hold0 Sell
Each firm's latest rating on GRAL in the past 90 days
Average 12-month target
$136.44
▲ 28.9% upside

Based on 9 analysts who set a price target on GRAL in the past 90 days. The average target is $136.44, with a high of $180.00 and a low of $100.00, compared with the last close of $105.88.

Low $100.00Avg $136.44High $180.00
Blue marker: last close $105.88
Highest target$180.00
Average target$136.44
Lowest target$100.00
Latest rating changes
Piper SandlerTarget raised
Nov 10Hold$54 → $130
RBC CapitalTarget raised
Nov 5Hold$84 → $100
Morgan StanleyMaintained
Oct 13Hold$120
TD CowenMaintained
Oct 13Buy$180
UBSTarget raised
Oct 2Buy$105 → $175
DateFirmActionRatingPrice target
Nov 10Piper SandlerTarget raisedHold$54 → $130
Nov 5RBC CapitalTarget raisedHold$84 → $100
Oct 13Morgan StanleyMaintainedHold$120
Oct 13TD CowenMaintainedBuy$180
Oct 2UBSTarget raisedBuy$105 → $175
Loading…

Technical Analysis

GRAL · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 24% below its 20 day and 16% below its 50 day average. It is 25% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot at $105.29, and the nearest resistance the Pivot R1 at $111.01.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.6%/day
Key levels
$166.4852 week high+57.2%
$144.18Swing high (Oct 14)+36.2%
$131.3820 day average+24.1%
$122.4750 day average+15.7%
$111.01Pivot R1+4.8%
$105.88Last close
$105.29Pivot−0.6%
$100.16Pivot S1−5.4%
$97.60100 day average−7.8%
$79.30200 day average−25.1%
$76.60Swing low (Aug 31)−27.7%
$41.5052 week low−60.8%
Indicators
RSI (14)37.86Weak, oversold below 30Neutral
MACD-4.02Below its signal lineBearish
Stochastic5.2Near the bottom of its rangeOversold
ADX (14)27.7Trending down
Williams %R-89.9Oversold below −80, overbought above −20Oversold
CCI (20)-154.4Oversold below −100, overbought above 100Oversold
Rate of change−24.1%Change over 10 sessionsBearish
ATR (14)$11.25Typical daily range, 10.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for GRAL

What happened before

See how GRAL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow is mixed2 bullish and 2 bearish whale options trades in the last 90 days. See Whale Flow

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D
Total alerts
4
Bullish
2
50%
Bearish
2
50%
Date span
Sep 17 – Nov 12
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$535K
Largest print
$535K
Loading…

GRAL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲208 buying vs 168 selling
  • ▼Held by funds -2.3 pts
  • ▲Funds holding +70
  • ▲Superinvestors: 2 added, 1 cut
  • ▲Put/call 1.62 to 0.50
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding448378+18.5%
In funds' top 10103+233.3%
Held by funds84.9%87.1%−2.3 pts
New / increased108 / 10060 / 120+15.6%
Reduced / sold out129 / 3997 / 49+15.1%
Put/call ratio0.501.62−69.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GRAL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRAL is in one of them and how their past GRAL trades turned out.

GRAL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GRAL in an article yet. Here's the latest on the wider market.

About GRAIL

GRAIL is a healthcare company based in Sunnyvale, California, that develops blood tests for early cancer detection. Its main product, Galleri, screens for many types of cancer from a single blood draw and aims to indicate the organ or tissue where a cancer signal may come from. The company sells Galleri through partnerships with healthcare systems, employers, digital health platforms, payors and life insurance providers. Galleri is not yet approved by the U.S. Food and Drug Administration.

Headquarters
Sunnyvale, CA
Founded
2015